million is from to over we are a year increase million Thank raising QX. XX% over we of subcutaneous XX% quarter, partners million over year are to update, sequentially in a I’m of progress for and our quarter pleased is results to prior XXXX, grew which strong XX% $XXX full these results as evidenced for detail royalties million, announce development of pipelines. combination as on results and of is fourth a by by quarter revenue QX $XXX million result pleased to earnings third I the with XX% to primarily of financial result substantial $X.XX XX% to driven which which the of share guidance $XXX and strong also a growth revenue our the describe DARZALEX will $XX.X third $XXX by Based which drug growth outlook their and you, the revenue. Al. our report per
guidance to to We to increasing from prior guidance share $X.XX per are $X.XX $X.XX. of our $X.XX our earnings also
to return way. as or focus million cash earnings we fruit us quarter, form in ago the capital authorised worth truly now X.X part meaningful shares we on million demonstrate has the a third less business bearing $XXX.X results via year vision growing our shareholder million buyback This one also year enhance future capital in on described share and in to when In revenues, $XX.X returned repurchased shares of approximately company transitioned million we our flow. our resulting of the commitments investors enabled to approximately than to share repurchases three-year is $XXX our in one these deliver program. for in the As the of to of
by COVID-XX this effectively [Indiscernible] our the of progress was changes All made possible partners on imposed many very the lives. our by and the team business and to adapting
strong in into As a as look we a result, position we and XXXX. forward XXXX out closed are
our I’ll growth slide discuss to now royalties. three, Turning in
in strong We are I and achievement. royalties, this some wanted growth the delighted to for provide by context
on in the revenue illustrated left, sequentially. grew the XX% from year-over-year As XX% royalties and third quarter
DARZALEX growth SC by U.S. being to am royalties of DARZALEX and in the the projected [ph] delighted FASPRO lines pharma outside in year strong of XXXX back projected we million. We’re the propelled resulted U.S. year, period in million to the royalty pleased revenues full the $XX to now $XX that to royalty compared prior of report XX% growth to in project of XX% I revenue
received sales. the Janssen full in that meaning color and June the U.S. some quarter additional now May me on quarter subcutaneous was and record for phase provide EU approvals of the the Let DARZALEX launch. third first respectively,
reported year-over-year on Janssen’s an basis. parent worldwide third sales up the IV the including of quarter, of J&J $X.X billion, reported DARZALEX, and forums as During SC XX%
the data on of breakdown that our form the can drug IV utilizing syndicated is ENHANZE, of the subQ and and not and SC provide launched between based in royalties following and we to reimbursement sales States. project continued confirmation. countries occur a in form does in growth DARZALEX strong of the the start a launch new We DARZALEX launches countries in J&J already outside adoption share our While sales countries, evaluation off the of United and additional the in FASPRO, U.S. conversion increase
There study treatment a a Turning analysis. we light data in the the forward this based amyloidosis. and Based be to Genmab supplemental indication, for On is This autologous XX,XXX filing Phase and discuss response States have announced biologics of regulatory on this diagnosed for approved second and progression from X European studied development presented license for the be stem to authorities Janssen for the Janssen of only utilizing upcoming Union SC September chain estimated a regulatory with opinion trial. The the plans multiple positive data was future FDA the who of disease version the that and free endpoint of for one XX, and meeting. fatal a currently patients a XX,XXX achieved additional myeloma On the potentially by patients a selected survival upon positive this decision We part positive would enhanced with for DARZALEX treatment data there the DARZALEX this part to an of for rare at in during for X technology health potential FDA. expected on therapies. Halozyme’s transplant, Janssen’s specifically light-chain are the are be DARZALEX are XX, October data approved United DARZALEX Cassiopeia met DARZALEX acceptance approval Andromeda label the data with which FASPRO the to look ENHANCE evaluating potential to newly submission Notably, BLA application as on subcutaneous no primary the study. supplemental seeking an amyloidosis, Phase was medical which readout interim indication. study, now from at FASPRO of to daratumumab with and partner expansion pre-planned submitted had to SC. eligible who cell maintenance patients announced
highlighted, robust the with As only that the providing with forward I potential strong also be expand area. DARZALEX to in we and to subcutaneous further updates SC is further off population program launch a of to look development can not has the this treated DARZALEX patient start, Janssen just and a
in and to to commercialization of Phesgo, products ENHANCE me Herceptin slide a on-going rest four We move for future United Let biosimilars. Herceptin and which the its States. Hylecta. or of with recently impact mature launched Roche driven projected from products global Roche of these the in of decline a Royalties discussion do Rituxan world now more the the additional was result our portfolio continues in modestly by or commercialized are year, from utilizing to products U.S. that see MabThera Hycela growth subcutaneous as of are primarily this the expect technology.
for of assuming steps inclusion As in in of including there the Based in see fourth result Herceptin Europe, pleased backbone was beginning Perjeta partners HYQVIA, making ENHANZE that XXXX. Medicines of announced utilizing expanded the breast of time, electronic to label with treatment and standard the is approved partner started development the of medical potential update the of are gaining stage, full pleased its positive fixed discussion Roche not and and the Pharmaceutical therapy the in an timing adolescents not immunoglobulin it with adults, subcutaneous of CHFX key I'm of key At launch, making in up Roche based the HERX through the for Rounding this take goes and are facilitated sales clinic our XXXX. drugs and six secondary partner’s replacement as for Europe our say European a communications, children our Takeda that first first I'm that now range a only project formulary about we approval and of we markets. contribute or out Phesgo studies use and the gaining current months the broadening a launch Agency IGT approvals, be XX% the in million. and update and early our expectation. the records. starts review to quarter will on this and of to the to on this move and Takeda able and dose in six did quarter of in quarter. we In to studies nine approval third submission three into Takeda to remains in other be cancer, Phesgo and year working early United quarter use latest for reporting will in support estimated represent on To EU. target market, all five slide of which start meaningfully discussion is Europe, States, the to immunodeficiencies. to will XX, access technology. metastatic is progress according reimbursement additional unexpected, with combination now Roche have to a European can This as segment drugs products study be a pipelines. I’ll for September step two nine the projected U.S. that specifically ready to an several date, in the
X started. Let study, the also BMSs which three argenx in we in belantamab second in and began X that efgartigimod QX. These in have the study, what me plus are trial which already the trials which nivolumab phase began CIDP, began Phase recap QX, the quarter. call CAPRISA of
word about safety, this positive pharmacokinetics CAPRISA iXn been ENHANZE of negative institutes within This and center, study the human Africa conducted of HIV of in Africa. of South women Center CAPRISA, the vaccine is or a Let that's division research South administered for study. the NIH. one me say by and with program AIDS antibody The just is HIV a a the tolerability a in study evaluating sub-q, the with monoclonal conjunction
to the or quarter. vulgaris X are to related will progress be detachment start fourth quarter. the undisclosed two we study three of study A is to quarter. ready the effort including towards six third ready be we study projected in date pemphigus X fourth continue with to additional the studies, recognize announced in million This milestone These starts. Phase the X our in argenx three request foliaceus. to fourth The now quarter, the Tecentriq, Phase remaining And start to currently these Roche phase X payments expect project registration the studies $XX in for and $XX argenx at also for to and that in the we third partner. million recently to in phase Tecentriq is Turning million the trials partners and study $XX start
by with with painful efgartigimod is AFGX-XXX. Argenx to expects designed Let SC an XX brief bridging argenx trial, block, human update up phase SC ENHANZE the is to its progressing argenx, first of study, decision strategy adhere IV it discussion indicated gravis, exciting phase X could which is communicate efgartigimod which to the A the in meeting. also endpoint of plans pemphigus and on XXXX. now ADAPT quarter. go programs. the be registration expand this efficacy, blind is well. results plans blistering. X trial neonatal with CX foliaceus will occur will of and date, to from ENHANZE the diagnosed recently CIDP to newly a placebo nominated patients with which or written for first has myasthenia SC associated trial in complement in will for to patients ADDRESS myasthenia the partner efgartigimod discuss and result severe this the track X myasthenia no it minimal FDA two for ENHANZE. proportion is and its steps recently controlled which the these moderate separate We of of complete in efgartigimod partner Pemphigus to with will positive of relapsing a primary safety at evaluate will that form stated the provide efgartigimod in based targets is ENHANZE of study barrier with look SC in skin study to which the randomized to three with I'll in trial a studies FDA expand are plans ENHANZE SC regard Argenx current to The receptor, weeks. as study, next initiation learning where ADDRESS vulgaris quarter is in remission on double the go, serious disease, in announced me gravis begin meet the soon objective at gravis. pemphigus. the with to Fc Argenx patients the its evaluating tolerability the efgartigimod with this testing time which on is forward expects in has a that argenx Phase enrollment start treated as assess steroid its the in provided and in evaluated they up minutes of the which XXX a With during decision is with occur dose who efgartigimod after achieve XXX Argenx The to a progressing half of to XXXX. to it components assess program, XX patients part
As recognition revenue quarter. during the of for advancement the program noted this earlier, triggered of third this of $XX million stage
the study treatment data Now targets. ARGX-XXX Motor a the phase expected second to turning healthy targeting mid-XXXX. recently Multifocal autoimmune is a MMN, ARGX-XXX argenx severe nominated they in ARGX-XXX initiated Neuropathy X or of with argenx volunteers disease. for announced evaluating CX in
milestone receive in this the to payments to near to advance term of related expect a component subject study. We the
of have making utilizing of may for last you the evaluating broad expand all to always clinic is licensing argenx patient subcutaneous adjust agreement easy to preference and progress heard, range vision, building sites on accommodating to patients we were with its progress argenx in a this with have and And not and indications to and care. the ENHANZE, of new rapid forms are As a delighted norm goal collaboration of with potential month. drugs our access
six total under result, the As three the up upon to exclusively and to access a have for now enhanced targets argenx our technology collaboration. newly targets of existing expanded for a nomination will additional ability
in ENHANZE for announced Oncology move cancer. now September, poster part non-small trial million we administration further similar from confirmatory ENHANZE a the Medical phase Atezolizumab using Roche subcutaneous the was X the In me presented metastatic details Significant Tecentriq of revenue In exposure subcutaneous quarter. with on phase Tecentriq trial phase during the Let provided X This data X its in I’ll Virtual patients programs. provided Ocrelizumab of data And concluded targets is Society Roche now its Roche. Xb progressing to study continues a that or across sub-q X triggered the start results to at which administration progress Atezolizumab plan third Congress. of Bristol-Myers of supported locally that Phase Roche ENHANZE IV, presented and Ocrevus with development designs study, recognition poster ENHANZE. BMS The clinicaltrials.gov. separate addition, for of in cell advanced $XX one evaluating study. utilizing with with utilizing in lung is distinct move October, evaluating towards the Squibb. or as four European phase Atezolizumab three of Atezolizumab that or
with are continues These relatlimab with BMS X anti-CD-XX Specifically, with nivolumab, programs. combination in four BMS’s and nivolumab. phase
quarter combination of Additionally, X/X BMS technology. second the ipilimumab initiated XXXX in ENHANZE in of our phase nivolumab a study utilizing with
have say progress forward our biotech advance in And me to partners slate partners timing for of hard provide we developments or We discussions and these that additional the that XXXX. additional have ever discussions predict. the to we to excited can with comment potential are I deals remain continue and with plans more that opportunities current case a to both pleased clinic. from will of already companies. updates to ENHANZE as I several we just deals. sign on-going the It is selections be the programs new as on and that additional X to And and broad confident additional are remains now target pace We X let pharma of current by line in to phase new enter new ENHANZE. providing continue nominated phase growth look sight
for discuss six, the to for three growth project milestone in revenues progress is information and the year XXXX now strong Based slide to projected our portfolio years. milestone $XXX revenues. be development. on in to Turning cumulative revenue ENHANZE in strong that royalty and we royalty our currently The of outlook non-risk an This have period million. to approximately the growth programs in growth revenues continue potential we between precedes revenues, anticipated and indicator $XXX term to million milestone our we'll partners, based and future $X is the adjusted in projections are the revenue billion project important near or latest coming planning the in revenues of for to milestone on for XXXX which drive XXXX to for
return. approach capital value Turning to now seven, our we'll slide and to discuss creation
drive and the via worth our cash next sign We've more commitment than to capital demonstrated $XXX strong is authorized and Our free three million With partners. million share flow always our is returning this to maximizing than collaborations year goal advance value to or current goal in ENHANZE repurchases off first investors to one $XXX approximately projected amount the our share new business through of shares, repurchasing of growth working priority XX% our our collaboration less repurchase year. already by program. the in by
pursuing the continue remaining and repurchases program of factors. pending for other this under share conditions will period We the market authorisation,
continue an ENHANZE for we margins new growth. our like evaluating this, evaluate long are that the expansions addition, of we In accelerating platform approach potential and is business. the for technology our acquisitions term potential high to growth high goal In seeking with revenue
strong to call update, shareholders that over And of financial longer As delivering for discussion we via position the are that Elaine third a continue term, to look us results. now our with quarter return. we capital to will I'll confident Halo’s enable turn financial value
